AMRXHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Amneal Pharmaceuticals, Inc. hold a median 12-month price target of $23 — +7.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Amneal Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AMRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | JP Morgan | Maintains | Overweight | $22 → $24 |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | $27 |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | — |
| 17 Sept 2026 | Barclays | Maintains | Overweight | $16 → $20 |
| 17 Sept 2026 | Barclays | Maintains | Overweight | — |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | — |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | $23 |
| 26 Aug 2026 | JP Morgan | Reinstates | Overweight | $22 |
| 3 Aug 2026 | UBS | Maintains | Buy | $23 → $25 |
| 3 Aug 2026 | UBS | Maintains | Buy | — |
| 15 July 2026 | UBS | Maintains | Buy | $19 → $23 |
| 15 July 2026 | UBS | Maintains | Buy | — |
| 20 May 2026 | Barclays | Maintains | Overweight | $15 → $16 |
| 20 May 2026 | Barclays | Maintains | Overweight | — |
| 17 Apr 2026 | UBS | Initiates | Buy | — |
| 2 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 31 Oct 2025 | Piper Sandler | Reiterates | Overweight | — |
| 16 Sept 2025 | JP Morgan | Maintains | Overweight | — |
| 3 Mar 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AMRX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Amneal Pharmaceuticals, Inc. returned +109.2% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 48% of US stocks
Cheaper than 1% of US stocks
Cheaper than 26% of US stocks
Higher than 53% of US stocks
Higher than 88% of US stocks
Higher than 52% of US stocks
Higher than 77% of US stocks
Higher than 60% of US stocks
Higher than 99% of US stocks
Higher than 90% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Amneal Pharmaceuticals, Inc. has a market value of $7.1B and an enterprise value of $9.3B.
Revenue in the twelve months to 30 June 2026: $3.1B. The latest quarter grew 9.9% year on year.
Net income over the same four quarters: $215.3M, a 6.9% net margin.
Diluted earnings per share, trailing twelve months: $0.49.
Free cash flow in the twelve months to 30 June 2026: −$12.3M.
Trailing P/E: 41.6×; forward P/E: 16.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Amneal Pharmaceuticals, Inc. employs 8,700 people — $358K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Amneal Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Amneal Pharmaceuticals has two key ingredients associated with a likely earnings beat in its upcoming report. The item says it outlines key expectations ahead of the report.
Why it matters — AMRX watchers may find the article's discussion of earnings expectations relevant ahead of the upcoming report.
Zacks Investment Research compares year-to-date performance for Amneal Pharmaceuticals and Iovance Biotherapeutics with their sector. The excerpt does not provide performance results.
Why it matters — The comparison may help AMRX watchers assess the stock’s year-to-date performance relative to its sector, but the excerpt gives no specific figures or conclusion.
Zacks Investment Research reported that implied volatility for Amneal Pharmaceuticals stock options is surging, citing recent movements in the options market.
Why it matters — AMRX watchers may note the reported change in options-market activity.
Zacks Investment Research says Amneal has an earnings-surprise history it describes as impressive and currently has two key ingredients that it views as supporting a likely beat in its next quarterly report.
Why it matters — AMRX watchers may note the report's favorable assessment of factors tied to the company's upcoming earnings announcement.
Amneal Pharmaceuticals announced that it will report third-quarter 2026 financial results before market open on November 3, 2026. The company will host an audio webcast at 8:30 a.m. ET.
Why it matters — AMRX watchers can note the scheduled date and time for the company’s third-quarter results and webcast.
The 7 Wall Street analysts covering Amneal Pharmaceuticals, Inc. have a median 12-month price target of $23, with estimates ranging from $20 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Amneal Pharmaceuticals, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amneal Pharmaceuticals, Inc. 89 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Amneal Pharmaceuticals, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +7.3% from the last close, and Ticker Nerd's factor model ranks Amneal Pharmaceuticals, Inc. 89 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Amneal Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $27 over the next 12 months.
Amneal Pharmaceuticals, Inc. returned +109.2% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a broad portfolio of essential medicines.
The most recent item we track (Zacks Investment Research, 27 Oct 2026): "Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?". Zacks Investment Research says Amneal Pharmaceuticals has two key ingredients associated with a likely earnings beat in its upcoming report. The item says it outlines key expectations ahead of the report.
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a broad portfolio of essential medicines. Its current business centers on generics, injectables, biosimilars, and specialty branded pharmaceutical products, serving patients and healthcare providers across the United States and other international markets. The company operates through three main segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment spans a wide range of dosage forms and delivery systems, including oral solids, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, and transdermal therapies. The Specialty segment focuses on branded treatments for selected therapeutic areas, while AvKARE supplies pharmaceuticals, medical, and surgical products and services to governmental agencies. Headquartered in Bridgewater, New Jersey, Amneal Pharmaceuticals plays a significant role in expanding access to cost-effective and differentiated medicines within the global pharmaceutical market.
CEO Mr. Chirag K. Patel · 8,700 employees · United States · https://www.amneal.com
